NEWS
ORACLE HEALTH JOINS THE REGENMED HUB
Oracle Health is the latest addition to the RegeneratOR ’ s Innovation Accelerator , located in the Regenerative Medicine Hub ( RegenMed Hub ), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter of Winston-Salem .
Oracle Health is committed to fostering a human-centric , global healthcare ecosystem by unifying data across an open , secure , cloudbased platform supported by applied AI-enabled clinical , payer and enterprise applications .
With these solutions , healthcare organisations can help improve patient outcomes , optimise clinical expertise and streamline operations .
“ Regenerative medicine holds tremendous promise in helping solve some of the most complex medical issues of our time and giving hope to patients dealing with organ failure and other related medical complications ,” said Rebecca Laborde , Vice President
of Clinical Health Innovation at Oracle . “ We have the opportunity to come together as a healthcare ecosystem to shape the future of precision medicine and care delivery . That ’ s why we are here and why we are proud to extend our long collaboration with Wake Forest to bring our clinical , data management and AI technology and expertise to this worthy and exciting field .”
PERSONALIS AND TEMPUS ENTERS A STRATEGIC COLLABORATION TO ADVANCE CANCER TESTING WITH AI
Personalis , a leader in advanced genomics for precision oncology and Tempus , a leader in Artificial Intelligence and precision medicine , has announced a strategic collaboration to co-commercialise NeXT Personal Dx , Personalis whole genome-based liquid biopsy laboratorydeveloped test ( LDT ) for detection of molecular residual disease ( MRD ) and recurrence in cancer NeXT Personal Dx is a leap forward in tumour-informed approaches , setting a new standard in performance of MRD tests with unprecedented sensitivity and high specificity . The test was launched by Personalis in October 2023 .
The two companies will work together exclusively in tumour-informed MRD testing for lung cancer , as well as breast cancer and immunotherapy monitoring after clinical validation of NeXT Personal Dx in those indications . The agreement contemplates testing up to tens of thousands of new patients over the next three years .
“ We believe that monitoring cancer recurrence is an important emerging development that has the potential to transform the way cancer is managed and Tempus is excited to bring this best-in-class tumour-informed test to oncologists to complement our existing tumour naïve MRD strategy ,” said Eric Lefkofsky , Founder and CEO of Tempus .
www . intelligenthealth . tech 7